Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Apr;14(4):805-808.
doi: 10.21037/jtd-22-181.

Multidisciplinary and real life data: practical management of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC)

Armida D'Incecco  1 , Katia Cannita  1 , Francesco Martella  1 , Andrea De Vico  2 , Gino Zaccagna  2 , Lorenza Landi  3 , Duilio Divisi  2
Affiliations
Editorial

Multidisciplinary and real life data: practical management of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC)

Armida D'Incecco et al. J Thorac Dis. 2022 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-22-181/coif). LL declares advisory role and speaker’s fee for BMS, MSB, AstraZeneca, Pfizer, Lilly, Bayer, Roche and Takeda, but it has no conflicts of interest with the manuscript. The other authors have no conflicts of interest to declare.

Comment on

References

    1. Sharma SV, Settleman J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev 2007;21:3214-31. 10.1101/gad.1609907 - DOI - PubMed
    1. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-11. 10.1073/pnas.0405220101 - DOI - PMC - PubMed
    1. Passaro A, Jänne PA, Mok T, et al. Overcoming therapy resistance in EGFR-mutant lung cancer. Nat Cancer 2021;2:377-91. 10.1038/s43018-021-00195-8 - DOI - PubMed
    1. Wu YL, Tsuboi M, He J, et al. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. N Engl J Med 2020;383:1711-23. 10.1056/NEJMoa2027071 - DOI - PubMed
    1. Du W, Zhao Y, Xuan Y, et al. Different efficacy in the non-small cell lung cancer patient with bilateral synchronous lesions treated with neoadjuvant gefitinib therapy: a case report. J Thorac Dis 2020;12:1582-7. 10.21037/jtd.2020.02.60 - DOI - PMC - PubMed